Selenium, Trace Elements and Transition Metals in Anticancer Drug Discovery

Dear Colleagues,

The search for new anticancer drugs and adjuvants in cancer therapy is an important challenge of the pharmaceutical sciences. Many in vitro and in vivo experimental models demonstrated the efficacy of Se compounds as anticancer agents. Selenocompounds possess the ability to interfere with the redox homeostasis and signalling of cancer cells to produce anticancer effects. Similarly, compounds and/or nanoparticles containing tellurium, cadmium, gold, rhodium and ruthenium have proven also to show anticancer effects. Taking into account their interesting activity, both selenocompounds, trace elements and transition metals are the object of intensive chemical modifications in order to find new active structures that can serve as a potential anticancer drug candidates or adjuvants in the future cancer therapy. In this Special Issue we want to present the recent advances in the drug design and potential pharmacological applications of all these elements. Articles that report the anticancer or cancer MDR reversing activity of novel compounds containing selenium, tellurium, or novel organic complexes of metals from the d-block are welcomed

Prof. Dr. Claus Jacob
Prof. Dr. Jadwiga Handzlik
Dr. Małgorzata Anna Marć
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.